本帖最后由 老马 于 2012-1-13 21:20 编辑
1 w Q0 q' e& F# i3 N5 X' Q% x1 o- B' Z, R% f' f- A
爱必妥和阿瓦斯丁的比较; A" i( B/ ]9 _ [- T: Q' o
) Y: S2 z& v/ L# t( a
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
8 G/ `; I% A$ ]8 E3 Y/ J
$ U' R) k" i/ g2 B
, d* {7 \, j! khttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
" ^2 l/ q* `' p2 L==================================================. D0 L# e$ `. p+ x. f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)$ _+ ~% X. {8 S; G0 C0 O, }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* ?6 r+ |3 ]" S2 C4 p" ?; z2 Y' i
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 B: M& S4 L) x2 T) C8 k$ |) z A! u
|